Literature DB >> 7395904

Frontometaphyseal dysplasia--evidence for X-linked inheritance.

R J Gorlin, R B Winter.   

Abstract

Fewer than two dozen cases of frontometaphyseal dysplasia have been reported, some doubly or erroneously. In most reports, no information is available on possible variable manifestations in female relatives. Statements that the disorder is inherited as a dominant trait, and as an X-linked recessive have caused us to consider genetic heterogeneity. A recent large kindred prompted us to survey all published examples. We asked authors to reexamine the families they studied for any expression in relatives. In some cases, no further information could be elicited, but some additional information was gathered and pedigrees modified. This evidence was sufficient to indicate X-linked inheritance, with severe manifestations in males and extremely variable manifestations in females.

Entities:  

Mesh:

Year:  1980        PMID: 7395904     DOI: 10.1002/ajmg.1320050111

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

Review 1.  International classification of osteochondrodysplasias. The International Working Group on Constitutional Diseases of Bone.

Authors:  J Spranger
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

2.  Hereditary multiple exostoses.

Authors:  R C Hennekam
Journal:  J Med Genet       Date:  1991-04       Impact factor: 6.318

3.  Sibs with mental retardation, supraorbital sclerosis, and metaphyseal dysplasia: frontometaphyseal dysplasia, craniometaphyseal dysplasia, or a new syndrome?

Authors:  W Reardon; C M Hall; M J Dillon; M Baraitser
Journal:  J Med Genet       Date:  1991-09       Impact factor: 6.318

Review 4.  Craniotubular bone disorders.

Authors:  R J Gorlin
Journal:  Pediatr Radiol       Date:  1994

5.  Treatment of obstructive uropathy in one of three young brothers suffering from Gorlin-Cohen syndrome: a case report.

Authors:  Ioannis Vakalopoulos; Spyridon Kampantais; Panagiotis Dimopoulos; Christos Papastavros; Vasileios Katsikas
Journal:  BMC Urol       Date:  2012-01-10       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.